BEC
GILD icon

Blue Edge Capital’s Gilead Sciences GILD Stock Holding History

Blue Edge Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-10,235
Closed -$733K – 81
2016
Q4 		$733K Sell
10,235
-345
-3% -$25.6K 0.41% 62
2016
Q3 		$837K Sell
10,580
-993
-9% -$80.7K 0.46% 62
2016
Q2 		$965K Hold
11,573
– – 0.53% 58
2016
Q1 		$1.06M Buy
11,573
+31
+0.3% +$2.8K 0.63% 50
2015
Q4 		$1.17M Buy
11,542
+76
+0.7% +$7.91K 0.76% 43
2015
Q3 		$1.13M Hold
11,466
– – 0.81% 43
2015
Q2 		$1.34M Sell
11,466
-105
-0.9% -$11.5K 0.88% 36
2015
Q1 		$1.14M Hold
11,571
– – 0.76% 41
2014
Q4 		$1.09M Buy
11,571
+12
+0.1% +$1.24K 0.75% 43
2014
Q3 		$1.23M Sell
11,559
-402
-3% -$39.4K 0.86% 33
2014
Q2 		$992K Hold
11,961
– – 0.67% 46
2014
Q1 		$848K Buy
+11,961
New +$938K 0.59% 50

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Blue Edge Capital's GILD Position: Q1 2017 in Review

Blue Edge Capital sold out of Gilead Sciences (GILD) in Q1 2017, closing a stake of 10,235 shares — an estimated $733K sold.

Blue Edge Capital first reported a position in GILD in Q1 2014 and held it in 12 quarters. The position peaked at $1.34M in Q2 2015. 1,524 funds tracked by Wall St. Rank hold GILD as of Q1 2017.

  • Blue Edge Capital reported no remaining Gilead Sciences position as of Q1 2017 after selling out during the quarter.
  • Blue Edge Capital sold 10,235 Gilead Sciences shares in Q1 2017, an estimated $733K.
  • Blue Edge Capital first reported a position in Gilead Sciences in Q1 2014 and held it in 12 quarters.
  • Blue Edge Capital's Gilead Sciences position peaked at $1.34M in Q2 2015.
  • 1,524 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2017.

Based on Blue Edge Capital's 13F filing for Q1 2017, filed 16 May 2017.